Branded, IPR-driven pharma player selling generics and OTC essential medicines across frontier markets in Latin America and Africa via a produce-stock-sell distribution model, now backward-integrating with its own India manufacturing plant.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 10 | 10 | 10 | 10 | 11 | 11 | 11 | 11 |
| Reserves | 18 | 55 | 103 | 173 | 190 | 221 | 227 | 238 |
| Borrowings | 0 | 4 | 4 | 13 | 19 | 53 | 57 | 58 |
| Other Liabilities | 8 | 31 | 60 | 43 | 38 | 25 | 28 | 30 |
| Total Liabilities | 36 | 100 | 176 | 240 | 258 | 310 | 322 | 337 |
| AssetsFixed Assets | 0 | 2 | 29 | 41 | 41 | 41 | 45 | 82 |
| CWIP | 0 | 0 | 1 | 3 | 2 | 22 | 34 | 0 |
| Investments | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 36 | 94 | 147 | 195 | 215 | 247 | 244 | 255 |
| Total Assets | 36 | 100 | 176 | 240 | 258 | 310 | 322 | 337 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | -2 | -14 | 0 | 34 | 6 | 5 | -35 | -4 |
| Cash from Investing | 0 | 0 | -6 | -28 | -11 | -1 | -22 | -21 |
| Cash from Financing | 0 | 18 | 4 | 0 | 26 | 30 | 34 | 0 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -2 | -14 | -3 | 7 | -9 | 4 | -57 | -25 |
| FCF Margin | — | — | — | — | — | — | — | — |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
BALAXI · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.